Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1082948

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1082948

Global Fungal Otitis Externa Market - 2022-2029

PUBLISHED:
PAGES: 185 Pages
DELIVERY TIME: 2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4350
PDF & Excel (Multiple User License)
USD 4850
PDF & Excel (Enterprise License)
USD 7850

Add to Cart

Market Overview

The global fungal otitis externa market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Inflammation of the external ear canal (redness and swelling) is caused by fungal otitis externa. Because repeated exposure to water can make the ear canal more vulnerable to inflammation, fungal otitis externa is also known as swimmer's ear.

Market Dynamics

The factors influencing the global fungal otitis externa market are the increasing research and development and the growing prevalence of fungal otitis externa.

The increasing research and development are expected to drive the market growth in the forecast period

Infection (usually bacterial but occasionally fungal) is the most common cause of otitis externa, but it can also be caused by various non-infectious systemic or local dermatologic processes. The most common symptom is discomfort that is limited to the external auditory canal, with the most common signs being erythema and canal swelling with variable discharge. The two most common precipitants of otitis externa are excessive moisture and trauma, which impair the canal's natural defenses, and avoiding these precipitants is the cornerstone of prevention. Cleaning the canal thoroughly is necessary for diagnosis and treatment, but flushing should be avoided. Otitis externa was so disabling in one recent study that it caused 36 percent of patients to miss work for a median of four days, with 21 percent requiring bed rest. Even though it is usually a localized process that can be easily controlled with topical agents, physicians treat this condition with systemic medications 65 percent of the time. If otitis externa is not treated properly, especially in immunocompromised patients, the infection can spread to the surrounding tissues and be fatal. Moreover, the Food and Drug Administration (FDA) approved Otiprio (ciprofloxacin otic suspension; Otonomy) 6 percent for the treatment of Pseudomonas aeruginosa and Staphylococcus aureus-related acute otitis externa (AOE) in children aged 6 months.

The side effects associated with the fungal otitis externa treatment are expected to hamper the market growth

An outer ear infection is treated with acetic acid (external otitis). It works by preventing bacteria and fungus from growing. But there may be some side effects associated with acetic acid. For instance, there may be some stinging or burning in the ear canal. This drug rarely causes a severe allergic reaction. However, suppose one notices any symptoms of a serious allergic reaction, such as a rash, itching/swelling (especially of the ear/face/tongue/throat), severe dizziness, or trouble breathing. In that case, they should seek medical help right away.

COVID-19 Impact Analysis

COVID-19 has the potential to impact the economy directly by affecting production and demand, disrupting distribution channels, and having a financial impact on businesses and financial markets. Several countries, including China, India, Saudi Arabia, the United Arab Emirates, Egypt, and others, are experiencing difficulties transporting drugs due to nationwide lockdowns from one location to another. Furthermore, due to the COVID-19 pandemic, players in the global fungal otitis externa market face major challenges on multiple fronts. The supply of raw materials required to manufacture drug formulations is a major challenge due to irregular transportation facilities. Furthermore, due to an increase in the number of patients suffering from COVID-19 and other life-threatening disorders, product distributors are experiencing irregular demand from retailers. Furthermore, the incidence of otitis externa increased in COVID-19 patients, according to an article published in the National Center for Biotechnology Information in August 2020. According to the findings, COVID-19 patients had an increased incidence of otitis externa, accounting for 18% of the study group out of 257 cases, with symptoms appearing primarily between the fifth and eighth days after infection.

Segment Analysis

Ear Drops segment is expected to dominate the market growth in the forecast period

The primary treatment for otitis externa includes pain management, debris removal from the external auditory canal (EAC), administration of topical medications to control edema and infection, and avoidance of contributing factors (OE). In most cases, over-the-counter analgesics and topical eardrops will suffice. Acetic acid drops, which change the pH of the ear canal, antibacterial drops, which control bacterial growth, and antifungal preparations are all common eardrops. Eczematoid (psoriatic) OE is usually treated with topical steroid drops, but it can be chronic or recurrent. Under a microscope, frequent suction debridement of the ear may be required. An ear wick may help deliver topical medications into the medial canal if there is significant canal edema.

Moreover, ear drops containing ciprofloxacin and dexamethasone are used to treat ear infections such as acute otitis externa and acute otitis media. Otitis externa, also called swimmer's ear, is a bacterial infection of the outer ear canal. Swelling, redness, and pain may occur in the ear canal and outer ear. Otitis media is a middle ear infection that affects children who have a tympanostomy (tube in the eardrum) to prevent too much fluid from entering the middle ear. Ciprofloxacin belongs to the fluoroquinolone antibiotics family of drugs. It works by either killing or preventing bacteria from growing. Dexamethasone is a steroid medication used to treat ear infections that cause redness, itching, and swelling.

Geographical Analysis

North America region is expected to hold the largest market share in the global fungal otitis externa market

The growing prevalence of fungal otitis externa and increasing research and development in this region is expected to drive the market growth.

In the United States, otitis externa is around 801 per 100,000 people. Bacteria cause 98 percent of acute otitis externa cases in North America. Pseudomonas aeruginosa and Staphylococcus aureus are the two most common isolates. Other aerobic and anaerobic bacteria, on the other hand, have been isolated in large numbers. Polymicrobial cases account for roughly one-third of all cases. Fungal pathogens, primarily Aspergillus and Candida species, are more common in tropical and subtropical environments and in patients who have previously received antibiotic treatment.

Competitive Landscape

The global fungal otitis externa market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Novartis, Sanofi, Par Pharmaceutical, Inc., Hi-Tech Pharma, Hill Dermaceuticals Inc, NuLife Pharmaceuticals, Pfizer Inc., Janssen Pharmaceutical, Mylan N.V., and Salvat Laboratories

Salvat Laboratories

Overview: The company is a family-owned pharmaceutical company founded in Barcelona in 1955 and currently managed by the third and fourth generations of the family. Salvat has over 400 employees in Spain, three manufacturing plants in Barcelona, Madrid, and Tamarac (Florida), two marketed products in the United States, and a broad international presence.

Product Portfolio: CETRAXAL OTICO 3 MG/ML is used to treat chronic suppurative otitis media (CSOM) and acute otitis externa (AOE) in adults and children over the age of two.

Why Purchase the Report?

Visualize the composition of the global fungal otitis externa market segmentation By drug type, route of administration, and distribution channel, highlighting the key commercial assets and players.

Identify commercial opportunities in global fungal otitis externa market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global fungal otitis externa market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global fungal otitis externa market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Product Code: DMPH5384

Table of Contents

1. Fungal Otitis Externa Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Fungal Otitis Externa Market- Market Definition and Overview

3. Fungal Otitis Externa Market- Executive Summary

  • 3.1. Market Snippet By Drug Type
  • 3.2. Market Snippet By Route of Administration
  • 3.3. Market Snippet By Distribution Channel
  • 3.4. Market Snippet By Region

4. Fungal Otitis Externa Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. The increasing research and development
    • 4.1.2. Restraints:
      • 4.1.2.1. The side effects associated with the fungal otitis externa treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Fungal Otitis Externa Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. Fungal Otitis Externa Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Fungal Otitis Externa Market- By Drug Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 7.3. Market Attractiveness Index, By Drug Type
    • 7.3.1. Ear Drops
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 7.3.1.1.3. Clotrimazole
      • 7.3.1.1.4. Fluconazole
      • 7.3.1.1.5. Acetic Acid (2%)
    • 7.3.2. Oral Medications
      • 7.3.2.1. Itraconazole
      • 7.3.2.2. NSAIDS
    • 7.3.3. Topical Medications

8. Fungal Otitis Externa Market-By Route of Administration

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.3. Market Attractiveness Index, By Route of Administration
    • 8.3.1. Otic
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.3.2. Oral
    • 8.3.3. Topical

9. Fungal Otitis Externa Market- By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Other

10. Fungal Otitis Externa Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Fungal Otitis Externa Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Fungal Otitis Externa Market- Company Profiles

  • 12.1. Salvat Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Novartis
  • 12.3. Sanofi
  • 12.4. Par Pharmaceutical, Inc.
  • 12.5. Hi-Tech Pharma
  • 12.6. Hill Dermaceuticals Inc
  • 12.7. NuLife Pharmaceuticals
  • 12.8. Pfizer Inc.
  • 12.9. Janssen Pharmaceutical
  • 12.10. Mylan N.V.

LIST NOT EXHAUSTIVE

13. Fungal Otitis Externa Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!